The informed consent for hereditary cancer
Por:
Alvarez-Gomez, Rosa Ma, Vargas-Huichochea, Ingrid, Herrera-Montalvo, Luis A., Alvarez-del Rio, Asuncion
Publicada:
1 ene 2023
Resumen:
The term Informed Consent (IC) refers to the indispensable communicative
process for the medical and research act, where a person approves the
performance of diagnostic and/or therapeutic actions, or involvement in
a research with full comprehension of the objective, benefits,
limitations and potential complications of the decision. The IC involves
indispensable ethical elements: a) information, sufficient and clear to
facilitate its understanding; b) the capacity of the person invited to
make decisions, being physically, mentally and legally competent, and c)
the voluntariness of the process, for a decision free of coercion. For
cancer predisposition molecular testing, IC bioethical challenges have
been documented, for example: clarification of complex information,
results of future relevance for health and family, the ownership of the
result, and the uncertainty value of certain results, among others.
There is a convergence of IC with genetic counseling, which aims to
educate about inherited diseases. Their apparent similarity has limited
the optimal performance of one or the other processes, restraining their
respective benefits. The present review seeks to provide an overview of
the status of IC in hereditary cancer, as cardinal point for improve its
application.
Filiaciones:
Alvarez-Gomez, Rosa Ma:
Inst Nacl Cancerol, Clin Canc Hereditario, Ciudad De Mexico, Mexico
UNAM, Area Humanidades Salud Bioet, Ciencias Med Odontol & Salud, Ciudad De Mexico, Mexico
Vargas-Huichochea, Ingrid:
UNAM, Fac Med, Div Invest, Dept Psiquiatria & Salud Mental, Ciudad De Mexico, Mexico
Herrera-Montalvo, Luis A.:
Inst Nacl Med Genom, Direcc Gen, Ciudad De Mexico, Mexico
Alvarez-del Rio, Asuncion:
UNAM, Fac Med, Div Invest, Dept Psiquiatria & Salud Mental, Ciudad De Mexico, Mexico
gold, Gold
|